Melissa L. Acreman

Melissa L. Acreman

Auto-generated profile, based on publicly available information

Melissa L. Acreman

Department of Obstetrics and Gynaecology Ipswich Hospital Ipswich Queensland Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MAMelissa L. Acreman
Melissa L. Acreman
SBSofia Bussolaro
Sofia Bussolaro
YRYvette C. Raymond
Yvette C. Raymond
IFIlaria Fantasia
Ilaria Fantasia
DRDaniel L. Rolnik
Daniel L. Rolnik
FCFabrício Da Silva Costa
Fabrício Da Silva Costa

8 February 2023 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
YRYvette C. Raymond
Yvette C. Raymond
MAMelissa L. Acreman
Melissa L. Acreman
SBSofia Bussolaro
Sofia Bussolaro
BMBWJ Mol
BWJ Mol
SFShavi Fernando
Shavi Fernando
DRDaniel Rolnik
Daniel Rolnik
Background: The performance of cell‐free DNA (cfDNA) screening for microscopic copy number variants (CNVs) is unclear.Objectives: This was a systematic review and meta‐analysis to investigate the sensitivity, specificity and positive predictive value (PPV) of cfDNA screening for CNVs.Search Strategy: Articles published in EMBASE, PubMed or Web of Science before November 2022 were screened for inclusion. This protocol was registered with PROSPERO (23 March 2021, CRD42021250849) prior to initiation.Selection Criteria: Articles published in English, detailing diagnostic outcomes for at least 10 high‐risk CNV results with cfDNA were considered for inclusion.Data Collection and Analysis: The PPV was calculated and pooled with random‐effects models for double‐arcsine transformed proportions, using cases with diagnostic confirmation. Overall sensitivity, specificity and a summary receiver‐operating characteristics (ROC) curve were calculated using bivariate models. The risk of bias was assessed using QUADAS‐2.Main Results: In all, 63 articles were included in the final analysis, detailing 1 591 459 cfDNA results. The pooled PPV was 37.5% (95% confidence interval [CI] 30.6–44.8), with substantial statistical heterogeneity (I2 = 93.9%). Bivariate meta‐analysis estimated sensitivity and specificity to be 77.4% (95% CI 65.7–86.0) and 99.4% (95% CI 98.0–99.8), respectively, with an area under the summary ROC curve of 0.947 (95% CI 0.776–0.984).Conclusions: Approximately one‐third of women who screen high‐risk for CNVs with cfDNA will have an affected fetus. This value is of importance for screening counselling.

1 June 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MBMichael Beckmann
Michael Beckmann
MAMelissa Acreman
Melissa Acreman
ESEmily Schmidt
Emily Schmidt
KMKatharina Merollini
Katharina Merollini
YMYvette Miller
Yvette Miller